Anuh Pharma board meet May 20, 2026: results, dividend

Meeting scheduled and what is on the agenda

Anuh Pharma has scheduled a board meeting for May 20, 2026. The agenda includes approval of the audited financial results for Q4 and the financial year ended March 31, 2026. The board will also consider a dividend for the year ended March 31, 2026. Alongside financial decisions, the meeting agenda includes the re-appointment of directors. The names listed for re-appointment are Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal.

For investors, this meeting matters because it typically sets the near-term information flow on audited numbers and shareholder payouts. Board actions on audited results and dividends are also closely tracked for compliance and timing, especially around record dates and shareholder approvals when applicable.

Trading window closure for designated persons

The company has stated that the trading window is closed from April 1 to May 22, 2026 for designated persons. Such closures are commonly linked to the period leading up to financial results, when unpublished price sensitive information may exist. The disclosed window end date extends beyond the meeting date, which is consistent with many internal compliance frameworks that keep the window closed until after outcomes are disseminated.

This is relevant for market participants because it signals that price-sensitive disclosures are expected around the meeting and immediate period after. It also indicates the company is following a structured schedule around results-related governance.

Directors up for re-appointment

The agenda includes re-appointment of two directors: Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal. Re-appointments are usually routed through board and shareholder processes based on tenure rules and governance requirements. In this case, the disclosed point is that their re-appointment will be considered at the May 20, 2026 board meeting.

Investors tend to watch such decisions for continuity in board oversight, especially when paired with annual financial approvals. The outcome, including any subsequent shareholder steps if required, will be clearer once the company issues the board meeting outcome.

Reference point: earlier FY25 board outcome

The article context also includes the company’s board outcome from May 23, 2025, which helps frame the type of decisions typically taken in this period. On May 23, 2025, the board approved audited financial results for the year ending March 31, 2025. It also approved a 1:1 bonus equity share issue. The bonus issue was described as 1 equity share of face value ₹5 each for every 1 fully paid-up equity share of face value ₹5 held, subject to shareholders’ approval via postal ballot.

For FY 2024-25, the board also proposed a final dividend of ₹1.50 per equity share on post-bonus equity share capital, subject to shareholder approval at the AGM. The same context states that bonus shares would also attract the proposed final dividend of ₹1.50 per share. These points show that the company’s May board meetings have previously combined audited results with capital and payout actions.

AGM timeline referenced in prior disclosures

From the May 23, 2025 outcome, the company also approved the draft notice for its 65th Annual General Meeting. The AGM was scheduled for Friday, August 22, 2025. Such items typically appear alongside audited results as boards approve statutory reports and meeting documentation.

While the May 20, 2026 meeting agenda in the provided text focuses on audited FY26 results, dividend consideration, and director re-appointments, the prior-year disclosure provides a pattern of governance and calendar alignment that investors often use for expectations on sequencing.

Product and regulatory mention: WHO prequalification

The provided text also mentions approval from the World Health Organization (WHO) Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP. No date, scope, or commercial detail is provided in the text beyond the approval reference. Still, the mention is notable because WHO PQ is widely tracked in pharmaceuticals, particularly where procurement and eligibility requirements link to international standards.

Given the limited details in the provided context, investors would typically wait for a fuller company disclosure to understand the exact product, site, scope, and implications.

Stock snapshot and what markets will watch

A price snapshot in the provided content shows Anuh Pharma at ₹81.19, up ₹1.43 (1.79%), timestamped Wed 20/05/2026 15:49:34, with the ticker shown as NSE: ANUHPHR. Market attention around this period is likely to remain on the audited FY26 numbers, the dividend decision, and the clarity on re-appointments.

Beyond the headline outcomes, investors usually look for the timing of result publication, any commentary embedded in filings, and the next steps for dividend approval where shareholder consent is required.

Key disclosed items at a glance

Recent board meeting timeline cited

The context includes a list of prior meeting dates with brief remarks. This helps track the company’s reporting rhythm across quarters.

Why the May 20, 2026 meeting is important

The combination of audited annual numbers and dividend consideration makes this a key governance event for FY26. Audited results anchor the company’s statutory reporting for the year ended March 31, 2026, and become the base for several shareholder communications. Dividend decisions also carry signalling value, but the only confirmed point here is that the board will consider a dividend for FY ended March 31, 2026.

Separately, director re-appointments can shape board continuity and oversight. Since the agenda explicitly names Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal, the market will likely watch for the final decision and the process that follows.

Conclusion

Anuh Pharma’s May 20, 2026 board meeting is set to cover audited FY26 results, a dividend proposal, and the re-appointment of two directors, with a trading window closure running through May 22, 2026. The next confirmed step for investors is the company’s formal outcome disclosure after the meeting, including audited figures and the board’s dividend recommendation, if approved.